Skip to Content

PGIM Jennison Health Sciences A PHLAX Fund Analysis

| Medalist Rating as of | See PGIM Investment Hub

Morningstar’s Analysis PHLAX

Will PHLAX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

Bold, yet appealing.

Senior Analyst Chris Tate

Chris Tate

Senior Analyst


PGIM Jennison Health Sciences’ deep domain expertise and distinctive approach make for an attractive healthcare offering.

Rated on Published on

Unlock our full analysis with Morningstar Investor